Glenmark Pharma sold its gynaecology business to private equity  Integrace Pharma in to cut down the debt of the company.

  Integrace will pay Rs 115 crore for four products of the portfolio that includes  Dubagest, Mumfer and Fenza. These three products currently have sales of Rs 60 crore and are growing by 15%.

The move is seen to offset the expenses associated with US investments which due to regulatory effects will take some time to be profitable.

According to CRISIL as warning letters doubles, Indian launches will take some time to be cleared for marketing which is going to affect the marketing cycle and late launches.